(“Sintana ”) and Challenger Energy Group plc (“Challenger ”) earlier today, we have reached another milestone associated with our proposed all-share acquisition of Challenger. A Scheme Document in ...

Based on strong preclinical data on HMPL-A251 in HER2-positive tumor cell lines, the firm wants to take the therapy into clinical trials by year end.

Gary Hattersley, chief scientific officer at Nuvation Bio ( NUVB +1.36%), exercised and immediately sold 100,000 shares of Class A common stock in an open-market derivative transaction on October 27, ...

Students – and all manner of professionals – are tempted to outsource their thinking to AI, which threatens to undermine learning and credibility. A philosophy professor offers a solution.

The FDA has approved Blenrep with BVd as a third-line treatment for relapsed or refractory multiple myeloma.

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 1 study titled ‘A Study to Learn About ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 4 study titled ‘A Phase 4 Study Using a ...

The antibody-drug conjugate, withdrawn from the market by GSK in 2022 after failing a confirmatory study, was approved ...

Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, ...

Merck KGaA could now have a head start in the race to market Precem-TcT, which could become the first widely approved ADC in ...

AN4035 is a proprietary CEACAM5-targeting antibody drug conjugate (ADC) designed to deliver potent anti-tumor activity with an improved therapeutic window. It is armed with Adlai Nortye’s ...

Bangladesh on Sunday launched its nationwide Typhoid Conjugate Vaccine (TCV) campaign, becoming the eighth country in the world to do so, in partnership with Unicef, Gavi, the Vaccine Alliance, and ...